India's Sun Pharma Advanced Research up on US FDA boost for glaucoma drug

Sun Pharma Advanced Research

14/07/2023 05:14

** Shares of Sun Pharma Advanced Research Co  SPRC.NS  rise
as much as 4.5% to 230.9 rupees
    ** Co said on Thurs that US FDA issued a Complete Response
Letter for application of glaucoma treatment, PDP-716
    ** Says FDA did not raise any issues with PDP-176's clinical
efficacy or safety and no additional data or trials requested
    ** Trading vol already at 0.5X the 30-day daily avg as of
9:38 a.m. IST
    ** Stock up almost 6% YTD as of last close
    

 (Reporting by Varun Vyas in Bengaluru)
 ((varunvyas.hebbalalu@thomsonreuters.com))